Trevi Therapeutics provided an update on its clinical development programs for Haduvio, an investigational therapy for chronic cough. The Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reached its 50% enrollment milestone.
The company expects the sample size re-estimation (SSRE) results for the CORAL trial in December 2024. Additionally, dosing for the Human Abuse Potential (HAP) study has been completed, with topline results also anticipated in December 2024.
The Phase 2a RIVER trial for refractory chronic cough (RCC) has enrolled its planned sample size and remains open for additional enrollment to meet stratification targets. Topline results for the RIVER trial are now expected in the first quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.